GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Price-to-Owner-Earnings

Immutep (Immutep) Price-to-Owner-Earnings : (As of Apr. 27, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Immutep Price-to-Owner-Earnings?

As of today (2024-04-27), Immutep's share price is $2.65. Immutep does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Immutep's Price-to-Owner-Earnings or its related term are showing as below:


IMMP's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-27), Immutep's share price is $2.65. Immutep's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.30. Therefore, Immutep's PE Ratio for today is At Loss.

As of today (2024-04-27), Immutep's share price is $2.65. Immutep's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.31. Therefore, Immutep's PE Ratio without NRI for today is At Loss.


Immutep Price-to-Owner-Earnings Historical Data

The historical data trend for Immutep's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Price-to-Owner-Earnings Chart

Immutep Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immutep Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immutep's Price-to-Owner-Earnings

For the Biotechnology subindustry, Immutep's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immutep's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Immutep's Price-to-Owner-Earnings falls into.



Immutep Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Immutep's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.65/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immutep  (NAS:IMMP) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Immutep Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Immutep's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Immutep (Immutep) Business Description

Traded in Other Exchanges
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.